|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,616.50 DKK | +0.53% |
|
+2.08% | -20.25% |
| 06-11 | Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits | MT |
| 06-10 | Nordic stocks in North America - Autoliv rose 1.6 percent | FW |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GENMAB A/S | Bio Therapeutic Drugs | +0.53% | +2.08% | -20.25% | +8.89% | -38.98% | 15.26B |  | |  |
- Stock Market
- Stocks
- GMAB Stock
- Charts Genmab A/S
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition